Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Jeffrey La Rosa is an analyst at Leerink Partners. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/29/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/03/2024 | JANX | Buy Now | Janux Therapeutics | $29.10 | 212.71% | Jeffrey La Rosa20% | $79 → $91 | Maintains | Outperform | Get Alert |
| 11/22/2024 | JANX | Buy Now | Janux Therapeutics | $29.10 | 171.48% | Jeffrey La Rosa20% | → $79 | Initiates | → Outperform | Get Alert |
| 01/23/2024 | PYXS | Buy Now | Pyxis Oncology | $1.07 | 1021.5% | Jeffrey La Rosa20% | → $12 | Initiates | → Outperform | Get Alert |
| 10/28/2022 | MRK | Buy Now | Merck & Co | $89.06 | 25.75% | Jeffrey La Rosa20% | $110 → $112 | Maintains | Outperform | Get Alert |
